[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580514":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":10,"centralContacts":42,"locations":48,"responsibleParty":64,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Chong Kun Dang Pharmaceutical","INDUSTRY",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"Metformin\u002FDPP4i\u002FSGLT2i",null,"Metformin + DPP4i 2-drug combination plus one of the SGLT-2i class of drugs.",[13,14],"Drug: SGLT2 inhibitor","Drug: DPP-4 inhibitor",{"label":16,"type":10,"description":17,"interventionNames":18},"Metformin\u002FDPP4i\u002FTZD","Metformin + DPP4i 2-drug combination plus one of the TZD class of drugs.",[19,14],"Drug: Thiazolidinedione",{"label":21,"type":10,"description":22,"interventionNames":23},"Metformin\u002FSGLT2i\u002FDPP4i","Metformin + SGLT2i 2-drug combination plus one of the DPP4i class of drugs.",[13,14],{"label":25,"type":10,"description":26,"interventionNames":27},"Metformin\u002FSGLT2i\u002FTZD","Metformin + SGLT2i 2-drug combination plus one of the TZD class of drugs.",[13,19],[29,34,38],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":10},"DRUG","SGLT2 inhibitor","SGLT2 inhibitor class of drugs",[9,21,25],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":10},"Thiazolidinedione","Thiazolidinedione class of drugs",[16,25],{"type":30,"name":39,"description":40,"armGroupLabels":41,"otherNames":10},"DPP-4 inhibitor","DPP4 inhibitor class of drugs",[9,16,21],[43],{"name":44,"role":45,"phone":46,"phoneExt":10,"email":47},"Soo Lim, M.D, Ph.D.","CONTACT","82-2-6373-0773","limsoo@snu.ac.kr",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":10,"country":54,"countryCode":10,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"Seoul National University Bundang Hospital","RECRUITING","Seongnam-si","Gyeonggi-do","South Korea",{"type":56,"coordinates":57},"Point",[58,59],127.13778,37.43861,{"lat":59,"lon":58},[62],{"name":44,"role":45,"phone":63,"phoneExt":10,"email":47},"1588-3369",{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100580514","korean-study-on-safety-and-effectiveness-of-oad-triple-therapy-in-type-2-diabetes-100580514",false,"NCT06838286","Korean Study on Safety and Effectiveness of OAD Triple Therapy in Type 2 Diabetes","A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic Mellitus Patients","TRIO","Inclusion Criteria:\n\n1. Patients with type 2 diabetes who are 19 years of age or older at the time of enrollment.\n2. Continued DPP-4i or SGLT-2i oral hypoglycemic combination therapy with metformin for at least 8 weeks prior to enrollment.\n3. 7.0% ≤ HbA1c \\\u003C 10.0% based on laboratory tests performed within 4 weeks of enrollment.\n4. Voluntarily give written informed consent after being told about the study.\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes and secondary diabetes.\n2. Patients receiving concomitant therapy with 3 or more oral hypoglycemic agents within 8 weeks of enrollment.\n3. Requiring treatment with insulin, GLP-1, etc. in addition to oral hypoglycemic agents during the study.\n4. End-stage renal disease and hemodialysis patients.\n5. diabetic ketoacidosis Patients.\n6. Pregnant and lactating women.\n7. Patients who are contraindicated by any of the \"Precautions for Use\" in the license for the drug being administered during the study, given the observational nature of the study under routine practice.\n8. Patients with a history of hypersensitivity to the investigational drug or any of its components or excipients.\n9. Anyone else deemed by the investigator to be unsuitable for participation in the study.","ALL","19 Years",{"count":77,"type":78},10000,"ESTIMATED","OBSERVATIONAL","A multicenter, prospective, non-interventional observation study to evaluate the safety and effectiveness of OAD triple therapy in Korean Type 2 diabetic mellitus patients.",[82],"Diabetes Mellitus, Type 2",[84,85,86,87],"Type 2 diabetes mellitus","Korean patients","Observational study","OAD triple therapy","2025-02-18",{"date":90,"type":91},"2025-02-20","ACTUAL",{"date":93,"type":91},"2024-03-16",{"date":95,"type":78},"2029-12-31",{"name":5,"class":6},1]